Drug Profile
Gallium citrate inhaled - Aridis Pharmaceuticals
Alternative Names: AR 501; gallium(III) citrate; PanaecinLatest Information Update: 11 Apr 2023
Price :
$50
*
At a glance
- Originator Aridis Pharmaceuticals
- Class Antibacterials; Antifungals; Antivirals; Citrates; Heavy metals; Radioisotopes; Small molecules
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 13 Mar 2023 Aridis Pharmaceuticals anticipates discussion with US FDA and EMA regarding results of the trial to plan the next study for the filing of a license application
- 13 Mar 2023 Aridis Pharmaceuticals completes a phase-I/II trials in Cystic fibrosis-associated respiratory tract infections in USA (Inhalation) (NCT03669614) (Aridis Pharmaceuticals pipeline, March 2023)
- 13 Mar 2023 Aridis Pharmaceuticals announces intention to submit regulatory applications to US FDA and EMA for Cystic fibrosis